Immix Biopharma (IMMX) Projected to Post Earnings on Thursday

Immix Biopharma (NASDAQ:IMMX - Get Free Report) is expected to issue its Q1 2025 quarterly earnings data before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.23) per share for the quarter.

Immix Biopharma (NASDAQ:IMMX - Get Free Report) last released its quarterly earnings results on Monday, March 24th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.09. On average, analysts expect Immix Biopharma to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Immix Biopharma Trading Down 3.9 %

Shares of NASDAQ:IMMX traded down $0.08 during mid-day trading on Tuesday, reaching $1.95. The company had a trading volume of 41,711 shares, compared to its average volume of 124,804. The firm has a market cap of $54.27 million, a price-to-earnings ratio of -2.29 and a beta of 0.27. Immix Biopharma has a one year low of $1.26 and a one year high of $2.71. The company's 50-day moving average price is $1.71 and its 200-day moving average price is $1.87.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a "buy" rating and set a $7.00 target price on shares of Immix Biopharma in a research report on Monday, February 10th.

Immix Biopharma Company Profile

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.